(Charlottetown, PE | August 25, 2015) CNS|CRO was among other world-renowned researchers who shared their research services and findings at NeuroConX 2015, an international innovation exchange conference focused on neurodegenerative disorders, from July 12-14, 2015 in Charlottetown, Prince Edward Island. Now in its fifth year, the conference is presented by the PEI BioAlliance and Neurodyn Life Sciences Inc. The 2015 theme was Proteinopathies of Neurodegenerative Disorders.
Daphne Gill, CNS|CRO’s Director of Operations, presented a poster on the preclinical neurological disease services of the contract research organization, including the latest portfolio of proprietary model offerings and development.
“CNS|CRO’s competence, flexibility, and cost competitiveness are widely recognized,” says Gill. “This conference was an opportune occasion to demonstrate the strength of our models for replicating the human disease condition, and for translating scientific discoveries into more successful therapies.”
New for 2015 is an autism spectrum disorder (ASD) behavioural test battery, an unparalleled method for assessing socio-communicative function in rats, as well as an electrophysiology platform for assessing sensory nerve conduction in vivo. This is in addition to a portfolio of highly predictive models of Parkinson’s disease, amyotrophic lateral sclerosis (ALS), epilepsy, and schizophrenia, as well as other conventional and proprietary behavioural tests.
About CNS|CRO: A wholly-owned subsidiary of Neurodyn Life Sciences Inc., CNS|CRO is a preclinical contract research organization offering a suite of animal models of neurological disease that are slowly developing and progressive, environmentally based, highly predictive, proprietary, and customizable.
For more information, please contact:
Daphne Gill, PhD | Director of Operations | CNS|CRO